Welcome to Prestigio Registry platform
Publications Page
Publication
Journal of Antimicrobial Chemotherapy
| July 2024
Polypharmacy, anticholinergic burden and drug-drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registry
M.Mazzitelli, D.Pontillo, T.Clemente, A.Di Biagio, G.Cenderello, S.Rusconi, B.Menzaghi, C.Fornabaio, E.Garlassi, M.Zazzi, A.Castagna, A.M.Cattelan; PRESTIGIO Study Group
Publication
Journal of Antimicrobial Chemotherapy
| July 2024
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry
D.Armenia, V.Spagnuolo, M.C.Bellocchi, L.Galli, L.Duca, G.Marchegiani, T.Clemente, L.Carioti, R.Lolatto, L.Calza, B.M.Celesia, A.Cascio, D.Francisci, A.Saracino, C.Torti, M.Zazzi, A.Castagna, M.M.Santoro; PRESTIGIO Study Group
Publication
Journal of Antimicrobial Chemotherapy
| July 2024
Risk of virological failure after drug burden reduction in people with 4-class drug-resistant HIV on virological suppression: A retrospective cohort analysis of data from the PRESTIGIO Registry
T.Clemente, S.Diotallevi, R.Lolatto, R.Gagliardini, A.Giacomelli, M.Fiscon, M.Ferrara, A.Cervo, L.Calza, F.Maggiolo, S.Rusconi, M.M.Santoro, A.Castagna, V.Spagnuolo; PRESTIGIO Study Group
Publication
BMJ Open
| February 2024
Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors
T.Clemente, L.Galli, R.Lolatto, R.Gagliardini, F.Lagi, M.Ferrara, A.M.Cattelan, E.Focà, A.Di Biagio, A.Cervo, L.Calza, F. Maggiolo, G.Marchetti, G.Cenderello, S.Rusconi, M.Zazzi, M.M.Santoro, V.Spagnuolo, A.Castagna; PRESTIGIO Study Group
Case Report
New microbiologica
| May 2023
PRESTIGIO RING: "A 59-year-old HIV-1 positive, highly treatment-experienced woman failing darunavir/ ritonavir plus raltegravir"
L.Labate, B.Bruzzone, V.Spagnuolo, M.Zazzi, M.M.Santoro, A.Di Biagio, A.Castagna et al.
Publication
International Journal of Antimicrobial Agents
| January 2023
Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry
F.Saladini, F.Giammarino, F.Maggiolo, M.Ferrara, G.Cenderello, B.M.Celesia, F.Martellotta, V.Spagnuolo, G.M.Corbelli, N.Gianotti, M.M.Santoro, S.Rusconi, M.Zazzi, A.Castagna, PRESTIGIO Study Group et al.
Publication
Journal of infection
| March 2022
Inflammation burden score in multidrug-resistant HIV-1 infection
T.Clemente, R.Caccia, L.Galli, A.Galli, A.Poli, G.Marchetti, A.Bandera, M.Zazzi, M.M.Santoro, P.Cinque, A.Castagna, V.Spagnuolo, PRESTIGIO Study Group et al.
Publication
Pharmacological Research
| February 2022
Leronlimab (PRO 140) in vitro activity against 4-class drug resistant HIV-1 from heavily treatment experienced subjects
S.Rusconi, F.Saladini, M.C.Bellocchi, L.Galli, R.Gagliardini, L.Gazzola, D.Francisci, F.Vichi, E.Focà, M.Zazzi, M.M.Santoro, A.Gabrieli, A.Castagna, PRESTIGIO Registry study group et al.
Publication
International Journal of Antimicrobial Agents
| January 2022
Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV
D.Armenia, M.M.Santoro, M.C.Bellocchi, L.Carioti, L.Galli, A.Galli, R.Scutari, E.Salsi, C.Mussini, G.Sterrantino, L.Calza, B.Rossetti, M.Zazzi, A.Castagna, PRESTIGIO Registry Study Group et al.
Publication
Open Forum Infectious Diseases
| September 2020
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry
L.Galli, M.R.Parisi, A.Poli, M.Menozzi, M.Fiscon, E.Garlassi, D.Francisci, A.Di Biagio, G.Sterrantino, C.Fornabaio, A.Degli Antoni, G.Angarano, F.M.Fusco, A.D'Arminio Monforte, G.M.Corbelli, M.M.Santoro, M.Zazzi, A.Castagna, PRESTIGIO Study Group et al.
Publication
Journal of Antimicrobial Chemotherapy
| September 2020
In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients
F.Saladini, A.Giannini, F.Giammarino, F.Maggiolo, F.Vichi, G.M.Corbelli, A.Galli, A.Bigoloni, A.Poli, M.M.Santoro, M.Zazzi, A.Castagna et al.
Publication
Journal of Acquired Immune Deficiency Syndromes
| August 2020
Simplification to High Genetic Barrier 2-Drug Regimens in People Living With HIV Harboring 4-Class Resistance Enrolled in the PRESTIGIO Registry
D.Canetti, L.Galli, N.Gianotti, A.Celotti, L.Calza, R.Gagliardini, S.Rusconi, S.Modica, G.Cenderello, M.Ferrara, M.M.Santoro, M.Zazzi, A.Castagna, PRESTIGIO Study Group et al.
Publication
International Journal of Antimicrobial Agents
| July 2020
Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen
M.M.Santoro, C.Fornabaio, M.Malena, L.Galli, A.Poli, M.Menozzi, M.Zazzi, K.L.White, A.Castagna, PRESTIGIO Study Group et al.
Publication
Journal of Antimicrobial Chemotherapy
| January 2018
Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus
A.Castagna, M.Ferrara, L.Galli, L.Comi, G.Sterrantino, G.Cenderello, M.Zaccarelli, E.Focà, A.Roncadori, A.Lazzarin, PRESTIGIO Study Group et al.
Observational collection of biological samples and data on clinical characteristics of PWLH.